CNS Pharmaceuticals, Inc. CNSP
Set alert
5.00 USD +0.23 +4.82%
At close · Oct 30
5.00 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
4.25 Day range 5.00
2.13 52-week range 7.84
- YTD
- -4.76%
- 1 year
- -33.42%
- Open
- 4.60
- Prev close
- 4.77
- Mkt cap
- 7.31M
- Vol
- 52.92K
- Avg vol
- 8.37K
- EPS
- -17.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.25
- High
- 5.00
- Forward P/E
- -0.28
- Beta
- 1.05
- Short ratio
- 0.04
- Inst. own
- 0.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.11872
- 200-d avg
- 4.42
- 1y target
- 0.50
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.25; estimate 0; surprise —%
- Feb 21, 2025Split: 1 for 50
- Jul 22, 2025Split: 1 for 12
Signals (68)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| SMA: Bearish | Oct 28, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| RSI: Oversold | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| SMA: Bearish | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 15, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 9, 2026 | 9 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 19, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 15, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 20, 2025 | 1 year ago |
| RSI: Oversold | Aug 14, 2025 | 1 year ago |
| RSI: Oversold | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| RSI: Oversold | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 2, 2025 | 1 year ago |
| RSI: Oversold | Apr 16, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 20, 2025 | 1 year ago |
| SMA: Bearish | Feb 19, 2025 | 1 year ago |
| RSI: Overbought | Feb 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 12, 2025 | 1 year ago |
| SMA: Bullish | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
Key statistics
- Market cap
- 6.27M
- Enterprise value
- 2.01M
- Trailing P/E
- 0.00
- Forward P/E
- -0.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -299.06
- Beta
- 1.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.19M
- Total cash
- 1.49M
- Total debt
- 123.25K
- Return on equity
- 0.00%
- Shares outstanding
- 57.49M
- Short % of float
- 2.79%
- 50-day average
- 0.11872
- 200-day average
- 4.42
Analyst view
Consensus: none
Price target (mean) 0.50
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CNSP Revenue — quarterly 0
CNSP Net income — quarterly -2.59M
CNSP EPS — quarterly -0.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.25 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -6.72 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -20.50 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -47.50 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -54.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -52.00 | — | — |
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cnspharma.com
News
- CNS Pharmaceuticals (NASDAQ:CNSP) Stock Jumps 1.5% – Here’s Why
- CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
- CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
- CNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) Estimate
- CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Your note
Sign in to keep a note on CNSP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLIMACO JOHN M | Chief Executive Officer | Purchase | Jan 31, 2024 | 215,676 |
| DOWNS CHRISTOPHER | Chief Financial Officer | Purchase | Jan 31, 2024 | 103,438 |
| EVANS CARL ANTHONY | Director | Purchase | Jan 31, 2024 | 33,458 |
| GUMULKA JERZY | Director | Purchase | Jan 31, 2024 | 43,006 |
| PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 27, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.35% | 203,180 | 22.15K | Sep 29, 2024 |
| UBS Group AG | 0.32% | 181,866 | 19.82K | Sep 29, 2024 |
| Virtu Financial LLC | 0.21% | 122,876 | 13.39K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.05% | 28,197 | 3.07K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.04% | 23,160 | 2.52K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 16,298 | 1.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.28% | 162,183 | 17.68K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 37,943 | 4.13K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 1,168 | 127 | Sep 29, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 8 | 0 | Sep 29, 2024 |